CD274 and cholangiocarcinoma: Socazolimab, a recombinant fully human anti-PD-L1 monoclonal antibody, was evaluated in a phase I clinical trial for its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with recurrent/metastatic CC who had failed or were intolerant to prior platinum-based therapy (178).